Imatinib Completed Phase 2 Trials for Chronic Myeloid Leukemia (CML) / Philadelphia-Positive Myeloid Leukemia Treatment

IndicationsStatusPurposePhase
CompletedTreatment2
clinicaltrials.gov IdentifierTitleDrugs
NCT00103844Dasatinib (BMS-354835) Versus Imatinib Mesylate in Subjects With Chronic Myeloid Leukemia